Related references
Note: Only part of the references are listed.Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides - a follow-up study from the DANBIO Registry
Lene Dreyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
Louise K. Mercer et al.
RHEUMATOLOGY (2013)
HIF-1α Acts Downstream of TNF-α to Inhibit Vasodilator-Stimulated Phosphoprotein Expression and Modulates the Adhesion and Proliferation of Breast Cancer Cells
Ke Su et al.
DNA AND CELL BIOLOGY (2012)
Does Cancer That Occurs During or After Anti-Tumor Necrosis Factor Therapy Have a Worse Prognosis? A National Assessment of Overall and Site-Specific Cancer Survival in Rheumatoid Arthritis Patients Treated With Biologic Agents
Pauline Raaschou et al.
ARTHRITIS AND RHEUMATISM (2011)
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
Johan Askling et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Proinflammatory Cytokines in Breast Cancer: Mechanisms of Action and Potential Targets for Therapeutics
Jodi E. Goldberg et al.
CURRENT DRUG TARGETS (2010)
Influence of Anti-Tumor Necrosis Factor Therapy on Cancer Incidence in Patients With Rheumatoid Arthritis Who Have Had a Prior Malignancy: Results From the British Society for Rheumatology Biologics Register
W. G. Dixon et al.
ARTHRITIS CARE & RESEARCH (2010)
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
Anja Strangfeld et al.
ARTHRITIS RESEARCH & THERAPY (2010)
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
J. P. Leombruno et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
Johan Askling et al.
ARTHRITIS AND RHEUMATISM (2009)
Risk of cancer among rheumatoid arthritis patients in California
Arti Parikh-Patel et al.
CANCER CAUSES & CONTROL (2009)
Biologic treatment of rheumatoid arthritis and the risk of malignancy - Analyses from a large US observational study
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
Enrico Flossmann et al.
LANCET (2007)
Tumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis
Soko Setoguchi et al.
ARTHRITIS AND RHEUMATISM (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)
J Ledingham et al.
RHEUMATOLOGY (2005)
A phase II study of etanercept (enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer
S Madhusudan et al.
CLINICAL CANCER RESEARCH (2004)
Breast cancer and NSAID use: a meta-analysis
SA Khuder et al.
BRITISH JOURNAL OF CANCER (2001)
Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice
B Knight et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
